Biocryst Pharmaceuticals (BCRX) Profit After Tax (2010 - 2026)
Biocryst Pharmaceuticals (BCRX) posted Profit After Tax of -$721.8 million for Q1 2026, down 3719.31% on a QoQ basis from -$18.9 million in Q4 2025, and down 297141.98% year-over-year from N/an in Q1 2025.
Biocryst Pharmaceuticals (BCRX) Profit After Tax (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals' Profit After Tax history runs 17 years deep, the most recent figure standing at -$721.8 million for Q1 2026.
- Quarterly Profit After Tax fell 297141.98% year-over-year to -$721.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$722.7 million (down 519.21% YoY) and the FY2025 annual result came in at -$883000.0, up 99.01% from the prior year.
- Profit After Tax was -$721.8 million for Q1 2026 at Biocryst Pharmaceuticals, down from -$18.9 million in the prior quarter.
- Across five years, Profit After Tax topped out at $12.9 million in Q3 2025 and bottomed at -$721.8 million in Q1 2026.
- A 5-year average of -$77.3 million and a median of -$42.5 million in 2022 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2025 — Profit After Tax jumped 191.92% — and 2026, when it slumped 297141.98%.
- Biocryst Pharmaceuticals' Profit After Tax stood at -$71.3 million in 2022, then climbed by 13.38% to -$61.7 million in 2023, then plunged by 46.2% to -$90.3 million in 2024, then soared by 79.06% to -$18.9 million in 2025, then tumbled by 3719.31% to -$721.8 million in 2026.
- Business Quant data shows BCRX's Profit After Tax at -$721.8 million in Q1 2026, -$18.9 million in Q4 2025, and $12.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 369.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.27 Bn | 2.20 Bn | 151.04 Mn | -721.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -721.81 Mn |
| Dec 31, 2025 | -18.90 Mn |
| Sep 30, 2025 | 12.90 Mn |
| Jun 30, 2025 | 5.09 Mn |
| Mar 31, 2025 | 243,000.00 |
| Dec 31, 2024 | -90.25 Mn |
| Sep 30, 2024 | -14.03 Mn |
| Jun 30, 2024 | -12.67 Mn |
| Mar 31, 2024 | -566,000.00 |
| Dec 31, 2023 | -61.73 Mn |
| Sep 30, 2023 | -36.04 Mn |
| Jun 30, 2023 | -75.33 Mn |
| Mar 31, 2023 | -53.33 Mn |
| Dec 31, 2022 | -71.27 Mn |
| Sep 30, 2022 | -42.52 Mn |
| Jun 30, 2022 | -58.86 Mn |
| Mar 31, 2022 | -74.20 Mn |
| Dec 31, 2021 | -17.61 Mn |
| Sep 30, 2021 | -58.77 Mn |
| Jun 30, 2021 | -43.20 Mn |